These current clinical drugs were respectively applied to treat PD caused by deficiencies of VMAT2 and TH in order to evaluate the therapeutic, adverse, and target variation effects; the computational results for various cases were listed in supporting information (S2 and S3 Tables). This evidence concerns the gene SLC18A2 and Parkinson disease.